Unicycive Therapeutics (UNCY) Notes Payables (2020 - 2023)
Unicycive Therapeutics' (UNCY) quarterly Notes Payables came in at $10.1 billion in Q2 2023, up 315404.85% on a QoQ basis from $3.2 million in Q2 2021.
Unicycive Therapeutics (UNCY) Notes Payables (2020 - 2023) Analysis & Trends
Unicycive Therapeutics (UNCY) has 3 years of Notes Payables data on file, last reported at $10.1 billion in Q2 2023.
- Quarterly Notes Payables changed N/A year-over-year to $10.1 billion in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $10.1 billion (changed N/A YoY) and the FY2020 annual result came in at $9000.0, changed N/A from the prior year.
- Notes Payables improved to $10.1 billion in Q2 2023, from $3.2 million in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $10.1 billion in Q2 2023 to a low of $9000.0 in Q4 2020.
- A 3-year average of $3.4 billion and a median of $3.2 million in 2021 frame the typical range for Notes Payables.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Unicycive Therapeutics | 151.01 Mn | 151.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 10.09 Bn |
| Jun 30, 2021 | 3.20 Mn |
| Dec 31, 2020 | 9,000.00 |